Survival score to characterize prognosis in inoperable stage III NSCLC after chemoradiotherapy.
Non-small cell lung cancer (NSCLC)
multimodal therapy
prognostic factors
survival-score
Journal
Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
entrez:
19
11
2019
pubmed:
19
11
2019
medline:
19
11
2019
Statut:
ppublish
Résumé
Stage III non-small cell lung cancer (NSCLC) represents a heterogeneous disease regarding principal patient- and tumor characteristics. A simple score may aid in personalizing multimodal therapy. The data of 99 consecutive patients with performance status ECOG 0-1 treated until the end of 2016 with multimodal approach for inoperable NSCLC (UICC 7 Most Patients were treated with concurrent (78%) or sequential (11%) chemoradiotherapy. 53% received induction chemotherapy. Median survival for the entire cohort was 20.8 (range: 15.3-26.3) months. Age (P=0.020), gender (P=0.007), pack years (P=0.015), tumor-associated atelectasis (P=0.004) and histology (P=0.004) had a significant impact on overall survival and were scored with one point each. Twelve, 59 and 28 patients were defined to have a low (0-1 points), intermediate (2-3 points) and high-risk (4-5 points) score. Median survival, 1-, 2- and 3-year survival rates were not reached, 100%, 83% and 67% in the low, 22.9 months, 80%, 47% and 24% intermediate and 13.7 months, 57%, 25% and 18% high-risk patients, respectively (P<0.001). Median survival was not reached in prospective cohort; analysis has revealed a trend for the 1-year survival rates with 100% for the low, 93% intermediate and 69% high-risk patients (P=0.100). The score demonstrated remarkable survival differences in inoperable stage III NSCLC patients with good performance status receiving multimodal therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Stage III non-small cell lung cancer (NSCLC) represents a heterogeneous disease regarding principal patient- and tumor characteristics. A simple score may aid in personalizing multimodal therapy.
METHODS
METHODS
The data of 99 consecutive patients with performance status ECOG 0-1 treated until the end of 2016 with multimodal approach for inoperable NSCLC (UICC 7
RESULTS
RESULTS
Most Patients were treated with concurrent (78%) or sequential (11%) chemoradiotherapy. 53% received induction chemotherapy. Median survival for the entire cohort was 20.8 (range: 15.3-26.3) months. Age (P=0.020), gender (P=0.007), pack years (P=0.015), tumor-associated atelectasis (P=0.004) and histology (P=0.004) had a significant impact on overall survival and were scored with one point each. Twelve, 59 and 28 patients were defined to have a low (0-1 points), intermediate (2-3 points) and high-risk (4-5 points) score. Median survival, 1-, 2- and 3-year survival rates were not reached, 100%, 83% and 67% in the low, 22.9 months, 80%, 47% and 24% intermediate and 13.7 months, 57%, 25% and 18% high-risk patients, respectively (P<0.001). Median survival was not reached in prospective cohort; analysis has revealed a trend for the 1-year survival rates with 100% for the low, 93% intermediate and 69% high-risk patients (P=0.100).
CONCLUSIONS
CONCLUSIONS
The score demonstrated remarkable survival differences in inoperable stage III NSCLC patients with good performance status receiving multimodal therapy.
Identifiants
pubmed: 31737496
doi: 10.21037/tlcr.2019.09.19
pii: tlcr-08-05-593
pmc: PMC6835102
doi:
Types de publication
Journal Article
Langues
eng
Pagination
593-604Informations de copyright
2019 Translational Lung Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
Lung Cancer. 2018 Aug;122:180-186
pubmed: 30032828
Br J Cancer. 2017 Aug 22;117(5):744-751
pubmed: 28728168
J Thorac Oncol. 2015 Nov;10(11):1576-89
pubmed: 26313682
Clin Lung Cancer. 2016 Nov;17(6):588-594
pubmed: 27378172
Br J Cancer. 2003 Sep 15;89(6):1028-30
pubmed: 12966420
Int J Radiat Oncol Biol Phys. 2018 Nov 1;102(3):543-551
pubmed: 30055239
Strahlenther Onkol. 2016 Apr;192(4):216-22
pubmed: 26809652
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Pneumonol Alergol Pol. 2016;84(3):186-92
pubmed: 27238182
J Clin Oncol. 2015 Dec 10;33(35):4194-201
pubmed: 26527789
Eur J Cancer. 2014 Nov;50(17):2939-49
pubmed: 25304298
N Engl J Med. 2018 May 24;378(21):1976-1986
pubmed: 29658848
J Clin Oncol. 2016 Mar 20;34(9):953-62
pubmed: 26811519
Chest. 2002 Sep;122(3):1037-57
pubmed: 12226051
Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1143-9
pubmed: 10613306
Br J Cancer. 2013 Oct 15;109(8):2066-71
pubmed: 24064979
Clin Oncol (R Coll Radiol). 2019 Feb;31(2):e1-e10
pubmed: 30415784
Radiat Oncol J. 2017 Jun;35(2):180-184
pubmed: 28712277
Clin Lung Cancer. 2016 Nov;17(6):558-562
pubmed: 27341791
Clin Lung Cancer. 2015 Mar;16(2):156-63
pubmed: 25467928
Cancer Treat Rev. 2018 May;66:114-121
pubmed: 29738940
Int J Radiat Oncol Biol Phys. 2015 Sep 1;93(1):72-81
pubmed: 26279026
Am J Cancer Res. 2015 Aug 15;5(9):2892-911
pubmed: 26609494
Rev Mal Respir. 2014 Mar;31(3):214-20
pubmed: 24680112
J Immunother Cancer. 2018 Jul 17;6(1):75
pubmed: 30012210
Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):452-461
pubmed: 29174428
J Thorac Dis. 2018 Apr;10(Suppl 9):S1108-S1112
pubmed: 29850190
J Geriatr Oncol. 2018 Sep;9(5):501-506
pubmed: 29848457
Lancet Oncol. 2015 Feb;16(2):187-99
pubmed: 25601342